EUCTR2013-000962-13-GB进行中（未招募）不适用
Evaluating the effects of the novel GLP-1 analogue, liraglutide, in patients with Alzheimer’s disease (ELAD study) - ELAD study
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male/female aged 50-85.
- •2. Capable of giving and capacity to give informed consent.
- •3. A carer who can act as a reliable study partner.
- •4. Diagnosis of probable Alzheimer's disease according to NIA-AA criteria.
- •5. Mini-Mental State Examination (MMSE) score of =22.
- •6. Rosen Modified Hachinski Ischemic score =4.
- •7. On stable medication for 3months; on or off Cholinesterase inhibitors.
- •8. Fluency in English and evidence of adequate premorbid intellectual functioning.
- •9.Likely to be able to participate in all scheduled evaluations and complete all required tests.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 136
排除标准
- •1.Any contraindications to the use of Liraglutide as per the Summary of Product Characteristics. (hepatic impairment, renal impairment with CKD stage 3 and above, inflammatory bowel disease).
- •2.Significant neurological disease other than AD that may affect cognition.
- •3.MRI/CT showing unambiguous aetiological evidence of cerebrovascular disease with regards to their dementia.
- •4.Diabetes Mellitus.
- •5.Currently taking or having taken memantine on the 30 days prior to screening.
- •6.Current presence of a clinically significant major psychiatric disorder (e.g. Major Depressive Disorder) according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
- •7.Current clinically significant systemic illness that is likely to result in deterioration of the patient’s condition or affect the patient’s safety during the study.
- •8. History of seizures, excluding febrile seizures in childhood.
- •9. Treatment with immunosuppressive medications (e.g. systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years.
- •10. Myocardial infarction within the last 1 year.
- •11. History of cancer within the last 5 years.
- •12. Other clinically significant abnormality on physical, neurological, laboratory, examination that could compromise the study or be detrimental to the patient.
- •13. History of alcohol or drug dependence or abuse within the last 2 years.
- •14. Current use of anticonvulsant, anti-Parkinson’s, anticoagulant (excluding the use of aspirin 325 mg/day or less) or narcotic medications.
- •15. Use of experimental medications for AD or any other investigational medication or device within 60 days. Patients who have been involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in that trial.
- •16. Women of childbearing potential. Women who could become pregnant will be required to use adequate contraception throughout the trial.
- •17. Patients with a personal or family history of medullary thyroid carcinoma (MTC) and patients with multiple endocrine neoplasia type 2 (MEN2).
研究者
相似试验
已完成
不适用
Study of the clinical effect of GLP-1 analogue for body weight, body fat, insulin secretion in patients with type 2 diabetesJPRN-UMIN000009638Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine130
进行中（未招募）
1 期
GLIDE: Gastric band and Liraglutide Intervention in Diabetes EvolutioThis trial will investigate the effects of the study treatment arms (gastric band + placebogastric band + liraglutide) on diabetes resolution in obese patients.MedDRA version: 14.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001538-41-GBniversity of Birmingham200
进行中（未招募）
1 期
GLIDE: Gastric band and Liraglutide Intervention in Diabetes EvolutioMedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersType 2 DiabetesEUCTR2015-005402-11-GBGuys and St Thomas NHS Foundation Trust58
已完成
不适用
GLIDE: Gastric band and Liraglutide Intervention in Diabetes EvolutioDiabetes mellitusISRCTN10551314IHR Guy's & St Thomas' NHS Foundation Trust (GSTFT)/King’s College London (KCL) Biomedical Research Centre152
进行中（未招募）
1 期
iraglutide to Short Bowel Syndrome, a cross-over studyShort bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytesrestricted oral/enteral nutrition to reduce intestinal lossesdisease-related hypophagialack of adaptive hyperphagiaaccelerated gastrointestinal transit timeMedDRA version: 19.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-000825-35-DKRigshospitalet Blegdamsvej16